Processa Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Processa Pharmaceuticals's earnings have been declining at an average annual rate of -32.5%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually.
Key information
-32.5%
Earnings growth rate
-7.7%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | n/a |
Return on equity | -222.9% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully
Dec 12Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?
Oct 20Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73
Aug 12We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully
Jul 07We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate
Jan 20Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans
Aug 26Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow
Jun 15What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?
Mar 15Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look
Jan 29How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?
Jan 20Revenue & Expenses BreakdownBeta
How Processa Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -11 | 6 | 6 |
30 Sep 23 | 0 | -22 | 7 | 8 |
30 Jun 23 | 0 | -26 | 9 | 10 |
31 Mar 23 | 0 | -28 | 10 | 11 |
31 Dec 22 | 0 | -27 | 9 | 11 |
30 Sep 22 | 0 | -18 | 7 | 10 |
30 Jun 22 | 0 | -15 | 6 | 9 |
31 Mar 22 | 0 | -13 | 5 | 7 |
31 Dec 21 | 0 | -11 | 5 | 7 |
30 Sep 21 | 0 | -23 | 5 | 7 |
30 Jun 21 | 0 | -23 | 4 | 5 |
31 Mar 21 | 0 | -20 | 3 | 4 |
31 Dec 20 | 0 | -19 | 3 | 3 |
30 Sep 20 | 0 | -6 | 2 | 2 |
30 Jun 20 | 0 | -4 | 2 | 2 |
31 Mar 20 | 0 | -4 | 2 | 2 |
31 Dec 19 | 0 | -4 | 2 | 2 |
30 Sep 19 | 0 | -3 | 1 | 2 |
30 Jun 19 | 0 | -3 | 1 | 2 |
31 Mar 19 | 0 | -3 | 1 | 3 |
31 Dec 18 | 0 | -4 | 1 | 3 |
30 Sep 18 | 0 | -4 | 1 | 3 |
30 Jun 18 | 0 | -4 | 1 | 3 |
31 Mar 18 | 0 | -3 | 1 | 2 |
31 Dec 17 | 0 | -2 | 1 | 1 |
31 Dec 16 | 0 | -2 | 0 | 2 |
Quality Earnings: PCSA is currently unprofitable.
Growing Profit Margin: PCSA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PCSA is unprofitable, and losses have increased over the past 5 years at a rate of 32.5% per year.
Accelerating Growth: Unable to compare PCSA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PCSA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).
Return on Equity
High ROE: PCSA has a negative Return on Equity (-222.91%), as it is currently unprofitable.